AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23984046 — intervention group
Group type: COMPARATOR
Intervention: Leucine (1 mmol/kg fat free body mass)
Number of subjects: 8
Study 23984046 — intervention group
Group type: COMPARATOR
Intervention: Phenylalanine (1 mmol/kg fat free body mass)
Number of subjects: 8
Study 23984046 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 8
Study 23984050 — intervention group
Group type: EXPERIMENTAL
Intervention: VBLOC device (Maestro Rechargeable System)
Number of subjects: 28
Study 23984053 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional and physical activity intervention (DVD and clinician toolkit)
Number of subjects: 0
Study 23984053 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 23984082 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg mifepristone daily for 3 months
Number of subjects: 220
Study 23984082 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg mifepristone daily for 3 months
Number of subjects: 220
Study 23984082 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 220
Study 23984185 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μCi of (131)I/mL thyroid tissue, corrected by 24-RAIU values (Group 1)
Number of subjects: 30
Study 23984185 — intervention group
Group type: COMPARATOR
Intervention: 200 μCi of (131)I/mL/24-RAIU (Group 2, historical control)
Number of subjects: 30
Study 23984729 — intervention group
Group type: COMPARATOR
Intervention: ALN-TTR01 (1.0 mg/kg)
Number of subjects: 49
Study 23984729 — intervention group
Group type: COMPARATOR
Intervention: ALN-TTR02 (0.15 to 0.3 mg/kg)
Number of subjects: 49
Study 23984897 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment options for ductal carcinoma in situ, specific interventions not detailed.
Number of subjects: 0
Study 23984897 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical clearance and radiation therapies, specific details not provided.
Number of subjects: 0
Study 23985703 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine combined with β-blocker (BB)
Number of subjects: 0
Study 23985703 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine combined with thiazide diuretic (TD)
Number of subjects: 0
Study 23985703 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine combined with angiotensin receptor blocker (ARB)
Number of subjects: 0
Study 23985703 — intervention group
Group type: COMPARATOR
Intervention: Benidipine-BB regimen
Number of subjects: 0
Study 23985703 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine-TD regimen
Number of subjects: 0
Study 23985804 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-wk very-low-energy diet
Number of subjects: 51
Study 23985804 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance after diet
Number of subjects: 51
Study 23985807 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 29
Study 23985807 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonoverweight adolescents)
Number of subjects: 29
Study 23986161 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene plus betamethasone dipropionate topical suspension
Number of subjects: 43
Study 23986162 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg BID for 12 weeks
Number of subjects: 30
Study 23986513 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX140-B treatment in diet-induced obese mice
Number of subjects: 0
Study 23986513 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX140-B treatment in both models
Number of subjects: 0
Study 23986513 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX140-B
Number of subjects: 0
Study 23987834 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 135
Study 23987834 — intervention group
Group type: EXPERIMENTAL
Intervention: Activin A (actA)
Number of subjects: 135
Study 23987834 — intervention group
Group type: COMPARATOR
Intervention: Conventional CV risk factors
Number of subjects: 135
Study 23988361 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT) with alteplase for 1-4 days
Number of subjects: 189
Study 23988361 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with 6 months of anticoagulation and 24 months of compression stockings
Number of subjects: 189
Study 23988361 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with post-thrombotic syndrome (PTS)
Number of subjects: 189
Study 23988636 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle insertion into fresh porcine shoulder tissue
Number of subjects: 82
Study 23988636 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle insertion into in vivo human tissues
Number of subjects: 82
Study 23989115 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR training intention
Number of subjects: 412
Study 23989115 — intervention group
Group type: EXPERIMENTAL
Intervention: Performing CPR intention
Number of subjects: 412
Study 23989115 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudinal beliefs
Number of subjects: 412
Study 23989115 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing CPR training intention
Number of subjects: 412
Study 23989115 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing CPR performance intention
Number of subjects: 412
Study 23989301 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial catheter ablation
Number of subjects: 37
Study 23989950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg daily continuously with a 28-day cycle)
Number of subjects: 37
Study 23990665 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 15
Study 23990869 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic Grade Index (GGI)
Number of subjects: 180
Study 23990869 — intervention group
Group type: EXPERIMENTAL
Intervention: MapQuant test
Number of subjects: 180
Study 23990869 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 180
Study 23991111 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 1 receptor antagonist (IL-1RA)
Number of subjects: 89
Study 23991111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-inflammatory mediators (CRP, IL-6, MCP-4)
Number of subjects: 89
Study 23991111 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune mediator network (IL-1RA, CRP, IL-6, MCP-4, MIP-1ß)
Number of subjects: 89
Study 23991111 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1RA
Number of subjects: 89
Study 23991111 — intervention group
Group type: EXPERIMENTAL
Intervention: Th1-associated mediators (IFNγ and IP-10)
Number of subjects: 89
Study 23993427 — intervention group
Group type: EXPERIMENTAL
Intervention: TCN-PM (triciribine phosphate monohydrate)
Number of subjects: 0
Study 23993936 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate values
Number of subjects: 174
Study 23993936 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of a primary care provider
Number of subjects: 174
Study 23993936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron administration
Number of subjects: 174
Study 23993936 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of intravenous fluids administered
Number of subjects: 174
Study 23993936 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline clinical dehydration score
Number of subjects: 174
Study 23993936 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bicarbonate values
Number of subjects: 174
Study 23994535 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 41
Study 23994535 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 41
Study 23994660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50mg to 200mg/day
Number of subjects: 31
Study 23996087 — intervention group
Group type: EXPERIMENTAL
Intervention: dmPGE2-treated UCB units
Number of subjects: 12
Study 23996484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Number of subjects: 0
Study 23996499 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriograph
Number of subjects: 22
Study 23996499 — intervention group
Group type: COMPARATOR
Intervention: Invasive measurement
Number of subjects: 22
Study 23996605 — intervention group
Group type: EXPERIMENTAL
Intervention: Water quality intervention
Number of subjects: 13760
Study 23996605 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation intervention
Number of subjects: 13760
Study 23996605 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing intervention
Number of subjects: 13760
Study 23996605 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 13760
Study 23996605 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined water+sanitation+handwashing (WSH) intervention
Number of subjects: 13760
Study 23996605 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined WSH+nutrition intervention
Number of subjects: 13760
Study 23996605 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13760
Study 23996808 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle mass index (SMI)
Number of subjects: 452
Study 23996808 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver attenuation index (LAI)
Number of subjects: 452
Study 23996808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of SMI
Number of subjects: 452
Study 23997960 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise with a stationary bicycle once a week for 30 minutes, under professional supervision.
Number of subjects: 116
Study 23997960 — intervention group
Group type: COMPARATOR
Intervention: Control group not engaged in any physical exercise.
Number of subjects: 116
Study 23998235 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 levels in exhaled breath condensates (EBC) in asthmatic patients
Number of subjects: 28
Study 23998235 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 levels in exhaled breath condensates (EBC) in asthmatic patients
Number of subjects: 28
Study 23998235 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT score in asthmatic patients
Number of subjects: 28
Study 23998235 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent predicted FEV1 in asthmatic patients
Number of subjects: 28
Study 23998235 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 levels in EBC in obese subjects
Number of subjects: 28
Study 23998235 — intervention group
Group type: COMPARATOR
Intervention: IL-2 and IL-10 levels in EBC in healthy volunteers (control)
Number of subjects: 28
Study 23999023 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interview and comprehensive assessment in stroke patients at risk of VCI
Number of subjects: 0
Study 23999023 — intervention group
Group type: EXPERIMENTAL
Intervention: New standardized evaluation battery of clinical, cognitive, behavioral and neuroradiological data
Number of subjects: 0
Study 23999023 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive assessment
Number of subjects: 0
Study 23999023 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of structured interview
Number of subjects: 0
Study 23999023 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent techniques for analysis of MRI data
Number of subjects: 0
Study 23999023 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid PET imaging
Number of subjects: 0
Study 23999023 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of modifiable vascular risk factors and secondary prevention of stroke recurrence
Number of subjects: 0
Study 24001117 — intervention group
Group type: EXPERIMENTAL
Intervention: Current triptan users
Number of subjects: 276
Study 24001117 — intervention group
Group type: COMPARATOR
Intervention: Discontinued triptan users
Number of subjects: 276
Study 24001117 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of efficacy
Number of subjects: 276
Study 24001117 — intervention group
Group type: EXPERIMENTAL
Intervention: MIDAS > 24
Number of subjects: 276
Study 24001117 — intervention group
Group type: EXPERIMENTAL
Intervention: BDI > 4
Number of subjects: 276
Study 24001117 — intervention group
Group type: EXPERIMENTAL
Intervention: History of opioid use
Number of subjects: 276
Study 24001117 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptan prescribed by a specialist
Number of subjects: 276
Study 24001117 — intervention group
Group type: EXPERIMENTAL
Intervention: Using at least 1 other abortive medication with triptan
Number of subjects: 276
Study 24001465 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Assessment Unit (SAU)
Number of subjects: 109
Study 24001465 — intervention group
Group type: COMPARATOR
Intervention: Emergency Department (ED)
Number of subjects: 109
Study 24001533 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab
Number of subjects: 0
Study 24001532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0
Study 24001532 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24002003 — intervention group
Group type: EXPERIMENTAL
Intervention: MediGuide Technology (MGT) for CRT implantation
Number of subjects: 15
Study 24002394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid balance (FB)
Number of subjects: 100
Study 24002394 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine (SCr)
Number of subjects: 100
Study 24002394 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine NGAL
Number of subjects: 100
Study 24002394 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-18
Number of subjects: 100
Study 24002394 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum MCP-1
Number of subjects: 100
Study 24002394 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha
Number of subjects: 100
Study 24002496 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib administered orally at escalating doses of 12 to 450 mg/day
Number of subjects: 76
Study 24002500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg orally on days 1 through 21 every 28 days until disease progression or intolerance
Number of subjects: 134
Study 24003046 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic cerebral MRI
Number of subjects: 120
Study 24003046 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetation length >4 mm
Number of subjects: 120
Study 24003046 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus IE
Number of subjects: 120
Study 24003046 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic IE
Number of subjects: 120
Study 24003046 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetation length (1 mm increase)
Number of subjects: 120
Study 24003088 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric orthokeratology (ortho-k)
Number of subjects: 80
Study 24003088 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 24004118 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening in the PanCan cohort
Number of subjects: 2961
Study 24004118 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening in the BCCA cohort
Number of subjects: 2961
Study 24004118 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive tools based on patient and nodule characteristics
Number of subjects: 2961
Study 24004540 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily Ropinirole prolonged release (RPR)
Number of subjects: 82
Study 24004540 — intervention group
Group type: COMPARATOR
Intervention: Once-daily Ropinirole prolonged release (RPR)
Number of subjects: 82
Study 24004540 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (once-daily and twice-daily RPR)
Number of subjects: 82
Study 24004642 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT interruption
Number of subjects: 5018
Study 24004642 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT disruption
Number of subjects: 5018
Study 24004642 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT cessation (overall)
Number of subjects: 5018
Study 24004642 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT discontinuation
Number of subjects: 5018
Study 24004642 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT disruption within 7 days
Number of subjects: 5018
Study 24004642 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT disruption 8-30 days
Number of subjects: 5018
Study 24004642 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT disruption more than 30 days
Number of subjects: 5018
Study 24004667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, dexamethasone, and rituximab (BDR) combination therapy
Number of subjects: 59
Study 24004934 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium (51.3 mmol/day)
Number of subjects: 695
Study 24004934 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium (307.8 mmol/day)
Number of subjects: 695
Study 24004934 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium with potassium supplementation (307.8 mmol sodium and 60 mmol potassium/day)
Number of subjects: 695
Study 24004934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 695
Study 24005614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib at a dose of 800 mg daily
Number of subjects: 5
Study 24005640 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital mortality
Number of subjects: 85
Study 24005640 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 85
Study 24005640 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 85
Study 24005640 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival time
Number of subjects: 85
Study 24005640 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of prehospital mortality
Number of subjects: 85
Study 24005640 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of in-hospital mortality
Number of subjects: 85
Study 24005640 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model significant determinants of mortality
Number of subjects: 85
Study 24006858 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at a dosage of 40 ppm
Number of subjects: 16
Study 24007627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and vinorelbine
Number of subjects: 38
Study 24007627 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA signature (miR-149 and miR-375)
Number of subjects: 38
Study 24007627 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic score including miR-200c, miR-424, miR-29c, and miR-124
Number of subjects: 38
Study 24007746 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m², Cyclophosphamide 600 mg/m², Trastuzumab 4 mg/kg (loading dose) on day 1 and 2 mg/kg on days 1, 8, and 15 during chemotherapy, followed by Trastuzumab 6 mg/kg every three weeks for 1 year.
Number of subjects: 493
Study 24007746 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and Cyclophosphamide combined with Trastuzumab
Number of subjects: 493
Study 24007819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5mg/kg, day 1), weekly paclitaxel (80 mg/m(2) days 1, 8, 15), and carboplatin (AUC6, day 1) intravenously q3w for 6-8 cycles, followed by single-agent bevacizumab for 1 year.
Number of subjects: 189
Study 24007819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing regimen
Number of subjects: 189
Study 24007969 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryton Side Branch Stent
Number of subjects: 252
Study 24008570 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use in hypercholesterolemia (HC)
Number of subjects: 558
Study 24008570 — intervention group
Group type: COMPARATOR
Intervention: Hypercholesterolemia without statin use
Number of subjects: 558
Study 24008570 — intervention group
Group type: COMPARATOR
Intervention: Normocholesterolemia
Number of subjects: 558
Study 24008739 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (1 dose)
Number of subjects: 74
Study 24008868 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D deficiency (< 20 ng/dL)
Number of subjects: 356
Study 24008868 — intervention group
Group type: EXPERIMENTAL
Intervention: Desirable concentrations (> 30 ng/dL)
Number of subjects: 356
Study 24008868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplements
Number of subjects: 356
Study 24008868 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentration
Number of subjects: 356
Study 24009136 — intervention group
Group type: EXPERIMENTAL
Intervention: ¹²³I-IBZM SPECT
Number of subjects: 10
Study 24009136 — intervention group
Group type: EXPERIMENTAL
Intervention: D2DR expression
Number of subjects: 10
Study 24009220 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH gel (80 units injected subcutaneously twice weekly)
Number of subjects: 24
Study 24009220 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH gel
Number of subjects: 24
Study 24009246 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stress response
Number of subjects: 0
Study 24009246 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn injuries
Number of subjects: 0
Study 24009417 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term application of noninvasive ventilation
Number of subjects: 0
Study 24009417 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24010976 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pulsatility index (PI) ≤ 0.80
Number of subjects: 53
Study 24010976 — intervention group
Group type: COMPARATOR
Intervention: Baseline pulsatility index (PI) > 0.80
Number of subjects: 53
Study 24010976 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cognitive improvement
Number of subjects: 53
Study 24010976 — intervention group
Group type: COMPARATOR
Intervention: Patients without cognitive improvement
Number of subjects: 53
Study 24010976 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PI ≤ 0.80
Number of subjects: 53
Study 24011220 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital diary (DiD)
Number of subjects: 700
Study 24011220 — intervention group
Group type: COMPARATOR
Intervention: Paper diary (PD)
Number of subjects: 700
Study 24013510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and capecitabine (first-line combination treatment)
Number of subjects: 44